Open AccessJournal Article
Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer
Saroj Vadhan-Raj,Jonathan C. Trent,Shreyaskumar Patel,Xiao Zhou,Marcella M. Johnson,Dejka M. Araujo,Joseph A. Ludwig,Shana O'Roark,Ann M. Gillenwater,Carlos E. Bueso-Ramos,Adel K. El-Naggar,Robert S. Benjamin +11 more
30
TL;DR: A single dose of palifermin before each cycle of chemotherapy reduced the incidence and severity of mucositis, and the drug was generally well tolerated, but most patients experienced thickening of oral mucosa.
read more
Abstract: Mucositis is a serious complication of cancer treatment that sometimes limits the dose and duration of chemotherapy. This small, randomized, placebo-controlled trial found that palifermin, a ketino...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines
TL;DR: The guidelines for treating oral and gastrointestinal mucositis due to cancer therapies such as high-dose chemotherapy and/or radiation continue to be an important clinical problem.
259
Oral complications in the treatment of cancer patients.
TL;DR: The prevalence and etiology of three broad categories of oral complications found during the treatment of cancer patients: mucositis, dysgeusia, and infectious disease are discussed.
143
Interventions for treating oral mucositis for patients with cancer receiving treatment.
J. E. Clarkson,Helen V Worthington,S. Furness,Martin McCabe,T. Khalid,Stefan Meyer +5 more
TL;DR: There is weak and unreliable evidence that low level laser treatment reduces the severity of the mucositis, and new interventions for treating mucositIS are needed.
120
Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem-Literature Review.
Aida Kusiak,Barbara Alicja Jereczek-Fossa,Barbara Alicja Jereczek-Fossa,Dominika Cichońska,Daniela Alterio +4 more
TL;DR: The possibilities of monitoring oral mucositis are described, taking into account the latest therapeutic achievements, includingphotobiomodulation, which brings analgesic and anti-inflammatory effects.
106
Prevention and Treatment of Oral Mucositis in Children with Cancer
TL;DR: This review will provide a comprehensive examination of available options for children who have oral mucositis and suggests Palifermin, a keratinocyte growth factor, may be a future option after its use in children is explored.
References
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
13.1K
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients
Stephen T. Sonis,Linda S. Elting,Dorothy M. K. Keefe,Douglas E. Peterson,Mark M. Schubert,Martin Hauer-Jensen,B. Nebiyou Bekele,Judith E. Raber-Durlacher,J. Peter Donnelly,Edward B. Rubenstein +9 more
TL;DR: An international multidisciplinary panel of experts assembled to create clinical practice guidelines for the prevention, evaluation, and treatment of mucositis.
1.7K
Purification and characterization of a newly identified growth factor specific for epithelial cells
Jeffrey S. Rubin,Hiroyuki Osada,Paul Finch,William G. Taylor,Stuart Rudikoff,Stuart A. Aaronson +5 more
TL;DR: The release of this growth factor by human embryonic fibroblasts raises the possibility that KGF may play a role in mesenchymal stimulation of normal epithelial cell proliferation, and Lack of mitogenic activity on either fibro Blasts or endothelial cells indicated that K GF possessed a target cell specificity distinct from any previously characterized growth factor.
914
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Ricardo Spielberger,Patrick J. Stiff,William I. Bensinger,Teresa Gentile,Daniel J. Weisdorf,Tarun Kewalramani,Thomas B. Shea,Saul Yanovich,Keith Hansen,Stephen J. Noga,John M. McCarty,C. Frederick LeMaistre,Eric C. Sung,Bruce R. Blazar,Dieter Elhardt,Mon-Gy Chen,Christos Emmanouilides +16 more
TL;DR: Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.